Epoch-making! Domestic independent research and development of innovative drugs is expected to upgrade "cocktail" therapy

This type of medicine, after 30 years, finally came out with innovation On November 30, the Bureau of disease control and Prevention released data: from January to October 2019, a total of 230 million people were tested nationwide In the new report, it was found that there were 131000 cases of infection, 127000 cases of new antiviral treatment were added The proportion of patients who met the treatment conditions in China receiving antiviral treatment was 86.6%, and the treatment power was 93.5% As of the end of October 2019, 958000 people have been reported alive in China Although the overall epidemic situation continues to be at a low epidemic level, the number of people infected each year is still increasing year by year The effective way to treat AIDS is antiretroviral therapy, commonly known as "cocktail therapy" Lourmidine (3TC) is the core drug of "cocktail therapy" According to statistics, at present, about 30 million people in the world are using 3TC, and the use rate of anti HIV treatment in China has reached 100% 3TC has been born for 30 years, and there are no innovative drugs in the same species, so many congenital defects such as high dosage, easy to produce drug resistance have not been solved Recently, azvudine, the first oral anti HIV drug in China with independent intellectual property rights and the support of national major science and technology special project of "major new drug creation", is applying for listing in advance with phase II clinical data, and is about to carry out phase III clinical trials, has attracted the attention of the industry, and is expected to end the 30-year non innovative drug listing situation in this field The results of the phase I and phase II clinical trials of azvudine showed that the therapeutic effect of azvudine was equivalent to that of 3TC, while the dosage of azvudine was only one percent of 3TC 3TC tablet is about 300mg, once a day On the one hand, the cost of patients is relatively high, and on the other hand, the dosage of azivudine is 3mg, which saves a hundred times of the dosage, but the effect is equivalent, which can fully reflect its high efficiency Some experts said that the emergence of azivudine has epoch-making significance and is expected to replace 3TC and become a new core drug in cocktail therapy It is well known that 3TC is more resistant Compared with lamivudine, which has been used for many years and produced a lot of drug resistance, the results of pre clinical drug resistance research show that azivudine is still effective against lamivudine resistant cell lines, which means that patients with lamivudine resistance still have therapeutic effect The results of antiviral test in vitro showed that half of the effective dose of azivudine was 0.03nm, but when the dose reached 100000 nm, there was no obvious side effect on cells, showing a high selectivity In addition, the results of pharmacokinetics in macaque and beagle dogs showed that in the target cells of HIV, the effective drug concentration in the peripheral blood mononuclear cells was maintained above 1.35pm within 5 days after treatment, which was enough to effectively inhibit the replication of HIV In addition, azivudine was added into the cells in advance in vitro, and then added into the virus four days later, still 100% inhibition Experts said that the next step of the drug will be to develop the direction of oral long-term, pre exposure prevention This indicates that azivudine is expected to become a long-term oral AIDS treatment drug, and may also play a key role in the prevention of AIDS Azfuding was developed by Henan real Biotechnology Co., Ltd for the purpose of developing the drug The company said it was mainly to provide better and safer drugs for Chinese patients At present, all the "cocktail therapy" used in China are imported original research drugs or domestic generic drugs, and the existing antiviral drugs have adverse reactions, drug resistance and other problems Although AIDS patients can get antiviral drugs free of charge for life, but the side effects of drugs suffer for a long time, as well as the high price of drugs at their own expense, many people will choose cross-border purchasing, illegal channels, to some extent, increasing the risk of uncertainty for the life of patients.